Elicio Therapeutics, Inc.
ELTX
$11.68
-$0.50-4.11%
NASDAQ
Corporate Info
Website
Phone Number
857 209 0050
Address
451 D Street
5th Floor
Suite 501
Boston, MA 02210
5th Floor
Suite 501
Boston, MA 02210
Country
United States
Year Founded
--
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
Business Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.